Recursion Pharmaceuticals, LLC
SALT LAKE CITY, UT · Founded 2013 · CIK 0001601830 · Biotech · Public
AI-powered drug discovery platform using computational biology and high-throughput phenotyping to identify and develop novel therapeutics
recursion.com →- Grants
- $4.2M
- 8 awards
- Sector median: 1
- Raised
- $466M
- 9 Form D · Sep 2020
- 73 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 13 granted · 27 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201320142015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $80,000 | |
| Private capital raised | Form D · SEC | $830,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Expansion of an efficient drug repurposing platform for rare genetic diseases. | $1,459,171 | |
| Federal grant | Department of Health and Human Services · Phase I · HLS13-04 High-Content High-Throughput Screen for Diamond Blackfan Anemia Treatments | $217,352 | |
| Federal grant | Department of Health and Human Services · Phase I · Application of an efficient drug repurposing platform to identify treatments for Cornelia De Lange Syndrome | $224,625 | |
| Private capital raised | Form D · SEC | $2,650,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Expansion of an efficient drug repurposing platform for rare genetic diseases. | $650,041 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction | $223,006 | |
| Private capital raised· 1 of 3 same day | Form D · SEC | $32,000,000 | |
| Private capital raised· 2 of 3 same day | Form D · SEC | $12,909,987 | |
| Private capital raised· 3 of 3 same day | Form D · SEC | $4,066,996 | |
| Private capital raised | Form D · SEC | $55,799,946 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction | $509,173 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction | $434,004 | |
| Private capital raised | Form D · SEC | $122,057,689 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction | $447,905 | |
| Private capital raised | Form D · SEC | $235,506,731 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2773 | StaphOff Biotech, Inc. | — | $25K |
| 2774 | Arsenal Biosciences | — | $579M |
| 2775 | Invivyd, Inc. | — | $489M |
| 2776 | Recursion Pharmaceuticals, LLC | — | $466M |
| 2777 | CARTESIAN THERAPEUTICS INC | — | $446M |
| 2778 | Genetic Networks, LLC | — | — |
| 2779 | FLUIDFORM INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- ZACHARY BOGUEDirector
- Blake BorgesonDirector · Executive Officer
- BLAKE BORGESONDirector · Executive Officer · Promoter
- TERRY-ANN BURRELLDirector
- R. CHAVEZDirector
- ZAVAIN DARDirector
- Perry FellDirector
- H. FELLDirector
- Christopher GibsonDirector · Executive Officer
- CHRISTOPHER GIBSONDirector · Executive Officer · Promoter
- ROBERT HERSHBERGDirector
- REID HUTCHINSDirector
- Dean LiDirector · Executive Officer
- DEAN LIDirector · Executive Officer · Promoter
- JOHN PEREIRAExecutive Officer
- MICHAEL SECORAExecutive Officer · Promoter
- Dean YiDirector · Executive Officer
Patents
- Detecting Analysis Model Compatibilities With Complex Experiment Designs To Generate Experiment Design And Analysis Model Compatibility Graphical User Interfacesgranted
- Utilizing Machine Learning And Digital Embedding Processes To Generate Digital Maps Of Biology And User Interfaces For Evaluating Map Efficacygranted
- Utilizing Masked Autoencoder Generative Models To Extract Cellular Response Representation Embeddingsapplication
- Utilizing Masked Autoencoder Generative Models To Extract Cellular Response Representation Embeddingsapplication
- MALT-1 Modulatorsgranted
- Generating Diverse And Novel Molecular Structures Using A Generative Stochastic Network With Synthesis Constraintsapplication
- Utilizing A Digital Phenomap And Germline Patient Data To Generate A Measure Of Target Discovery Power And Gene Targetsapplication
- Generating Separability And Disjointness Measures For Pairwise Interaction Detection And Active Learningapplication
- Generating Separability And Disjointness Measures For Pairwise Interaction Detection And Active Learningapplication
- Generating Enhanced Biological Representations Utilizing Knowledge Distillationapplication
- Generating Augmented Biological Datasets Via Batch Correction Techniquesapplication
- Generating Transcriptomic Benchmarks For Transcriptomics Machine Learning Models Utilizing A Structural Integrity Metricapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.